{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:57:39Z","timestamp":1760061459455,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011665","name":"King Saud University Deanship of Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jpba.2021.114023","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T02:09:32Z","timestamp":1615514972000},"page":"114023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A simple and sensitive HILIC-based UHPLC-MS\/MS method for quantifying of rivaroxaban in dried blood spots: Application in comparison with the plasma sample method"],"prefix":"10.1016","volume":"198","author":[{"given":"Muzaffar","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3298-9672","authenticated-orcid":false,"given":"Zabih","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essam","family":"Ezzeldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasr Y.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser S.","family":"Al-Shakliah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Alrasheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishtiaque","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-2382","authenticated-orcid":false,"given":"Luluh","family":"Albehlal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114023_bib0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.medcli.2017.11.042","article-title":"Direct oral anticoagulants: an update","volume":"151","author":"Franco Moreno","year":"2018","journal-title":"Med. Clin. (Barc)."},{"key":"10.1016\/j.jpba.2021.114023_bib0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010","journal-title":"Ther. Drug Mont."},{"key":"10.1016\/j.jpba.2021.114023_bib0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/nyas.12136","article-title":"Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions","volume":"1291","author":"Sarich","year":"2013","journal-title":"Ann. New York Acad. Sci."},{"year":"2019","series-title":"US Prescribing information","author":"XARELTO\u00ae (rivaroxaban) tablets","key":"10.1016\/j.jpba.2021.114023_bib0020"},{"key":"10.1016\/j.jpba.2021.114023_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb. J."},{"key":"10.1016\/j.jpba.2021.114023_bib0030","first-page":"A656","article-title":"Pulmonary embolism due to interaction between rivaroxaban and carbamazepine","volume":"157","author":"Risselada","year":"2013","journal-title":"Ned tijdschrift voor geneeskunde"},{"key":"10.1016\/j.jpba.2021.114023_bib0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jpba.2021.114023_bib0040","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2021.114023_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12959-018-0183-3","article-title":"Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study","volume":"16","author":"Sennesael","year":"2018","journal-title":"Thromb. J."},{"key":"10.1016\/j.jpba.2021.114023_bib0050","first-page":"e13104","article-title":"Routine coagulation test abnormalities caused by rivaroxaban: a case report","volume":"97","author":"Song","year":"2018","journal-title":"Bull. Sch. Med. Md"},{"key":"10.1016\/j.jpba.2021.114023_bib0055","doi-asserted-by":"crossref","first-page":"382","DOI":"10.12998\/wjcc.v7.i3.382","article-title":"Considerations for routine coagulation monitoring with rivaroxaban: a case report and review of the literature","volume":"7","author":"Wu","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.jpba.2021.114023_bib0060","first-page":"000937","article-title":"A low rivaroxaban plasma level may indicate anticoagulation undertreatment","volume":"5","author":"Romano","year":"2018","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"10.1016\/j.jpba.2021.114023_bib0065","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/FJC.0000000000000870","article-title":"Therapeutic drug, monitoring of direct oral anticoagulants may increase their benefit-risk ratio","volume":"76","author":"Bernier","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jpba.2021.114023_bib0070","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jth.13747","article-title":"Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels","volume":"15","author":"Studt","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jpba.2021.114023_bib0075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1160\/TH13-04-0274","article-title":"F. Mullier., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with rivaroxaban","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jpba.2021.114023_bib0080","first-page":"129","article-title":"Determination of direct oral anticoagulants from human serum samples","volume":"40","author":"Harenberg","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jpba.2021.114023_bib0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00228-019-02693-2","article-title":"Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation","volume":"75","author":"Mikli\u010d","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2021.114023_bib0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11239-014-1121-2","article-title":"A validated high-throughput UHPLC-MS\/MS assay for accurate determination of rivaroxaban in plasma sample","volume":"39","author":"Iqbal","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.jpba.2021.114023_bib0095","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11239-019-02022-5","article-title":"Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect","volume":"49","author":"Anwer","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.jpba.2021.114023_bib0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpba.2017.11.079","article-title":"Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection","volume":"150","author":"Hahn","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114023_bib0105","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.clinbiochem.2016.05.004","article-title":"Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring","volume":"49","author":"Antunes","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2021.114023_bib0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpba.2016.06.026","article-title":"J. Burhenne., Clinical feasibility of dried blood spots: analytics, validation, and applications","volume":"130","author":"Enderle","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114023_bib0115","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1021\/acs.analchem.8b02046","article-title":"J. Burhenne., Dried-blood-spot technique to monitor direct oral anticoagulants: clinical validation of a UPLC-MS\/MS-based assay","volume":"90","author":"Foerster","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2021.114023_bib0120","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1021\/acs.analchem.9b04063","article-title":"Using the PCI-IS method to simultaneously estimate blood volume and quantify nonvitamin K antagonist oral anticoagulant concentrations in dried blood spots","volume":"92","author":"Jhang","year":"2020","journal-title":"Anal. Chem."},{"year":"2013","series-title":"Guidance for Industry: Bioanalytical Method Validation. US","author":"Food and Drug Administration","key":"10.1016\/j.jpba.2021.114023_bib0125"},{"year":"2013","series-title":"Guideline on Bioanalytical Method Validation","key":"10.1016\/j.jpba.2021.114023_bib0130"},{"key":"10.1016\/j.jpba.2021.114023_bib0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2021.114023_bib0140","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jchromb.2009.01.003","article-title":"Validation of bioanalytical LC-MS\/MS assays: evaluation of matrix effects","volume":"877","author":"Van Eeckhaut","year":"2009","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2021.114023_bib0145","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4155\/bio.11.191","article-title":"EBF and dried blood spots: from recommendations to potential resolution","volume":"3","author":"Timmerman","year":"2011","journal-title":"Bioanalysis"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521001357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521001357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:13:42Z","timestamp":1760001222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521001357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"alternative-id":["S0731708521001357"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114023","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A simple and sensitive HILIC-based UHPLC-MS\/MS method for quantifying of rivaroxaban in dried blood spots: Application in comparison with the plasma sample method","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114023"}}